Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2024 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.300-2.500 for the period, compared to the consensus earnings per share estimate of 2.340. The company issued revenue guidance of $16.0 billion-$16.4 billion, compared to the consensus revenue estimate of $16.0 billion. Teva Pharmaceutical Industries also updated its FY24 guidance to $2.30-2.50 EPS.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.55 during midday trading on Friday, reaching $16.99. The company had a trading volume of 12,080,645 shares, compared to its average volume of 10,327,264. The company has a market capitalization of $19.24 billion, a price-to-earnings ratio of -41.44, a price-to-earnings-growth ratio of 1.54 and a beta of 0.90. The stock has a 50 day moving average price of $16.79 and a 200-day moving average price of $14.74. Teva Pharmaceutical Industries has a 1-year low of $8.06 and a 1-year high of $18.02. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.61.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $3.82 billion for the quarter, compared to the consensus estimate of $3.70 billion. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

TEVA has been the subject of several research analyst reports. StockNews.com raised Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research report on Saturday. Bank of America increased their price target on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a buy rating in a research note on Thursday, May 30th. Argus upgraded Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $20.00 price target for the company in a research note on Wednesday, July 10th. Barclays increased their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an overweight rating in a research note on Thursday. Finally, Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $18.67.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the sale, the director now owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The disclosure for this sale can be found here. Insiders sold 549,719 shares of company stock worth $9,353,736 over the last quarter. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.